$599

Pfizer and Vertex Q1 ’26 Earnings; Madrigal Partners for siRNA MASH Asset; Novo Evaluates New Dose of Cagrisema; Cytokinetics Shares Topline ACACIA-HCM Results

A series of cardiometabolic-related news items has been observed by Pfizer, Madrigal Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here